BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
/ 220 items
#andre↓
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares
Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.
Palantir Expands into Aviation and Secure AI with Surf Air and Nvidia Partnerships
Palantir deepens its aviation push with Surf Air Mobility on OperatorOS and partners with Nvidia to deploy secure AI models for government and critical infrastructure.
Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.
TeraWulf’s Aggressive HPC and AI Push Wins Citi Backing
Wall Street consensus is Strong Buy at $36.34, implying 40% upside as the company pivots aggressively into AI and HPC infrastructure.